Dr Magovcevic-Liebisch is an accomplished pharmaceutical and biotechnology executive with over 25 years of leadership experience; Dr Ruth McKernan FMedSci CBE, co-founder and Inte ...
Neurocrine Biosciences has penned a deal with China’s TransThera Sciences potentially worth more than $880 million in biobucks for inhibitors aimed at a red-hot inflammation target. | Neurocrine ...
Pharma announced positive topline results from CALIBRATE, its global Phase 3 study of encaleret in autosomal dominant ...
Neuropsychiatric disorder specialist MapLight Therapeutics has made its debut on the Nasdaq, raising $251 million and ...
Investing.com -- Neumora Therapeutics Inc (NASDAQ:NMRA) stock jumped 8.4% in premarket trading Monday after the company reported positive preclinical data for its obesity drug candidate and received ...
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora's M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical stud ...
TipRanks on MSN
Neumora Therapeutics Begins Phase 1 Study for NMRA-898
The latest announcement is out from Neumora Therapeutics, Inc. ( ($NMRA) ). On October 27, 2025, Neumora Therapeutics announced the initiation of ...
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical ...
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback